 "BSE Midcap index hits new high led by auto, consumer discretionary stocks")
The S&P BSE Midcap index hit a record high of 21,254.92, up 2 per cent on the BSE in the intra-day trade on Tuesday, on the back of a strong rally in automobile, consumer discretionary, financials and Adani Group stocks. The index surpassed its previous high of 21,085.51 touched on March 4, 2021 in the intra-day trade.
At 02:07 pm, the S&P BSE Midcap index was the top gainer among broader indices, up 1.7 per cent at 21,196.55 levels. In comparison, the S&P BSE Smallcap index was up 1.2 per cent and the benchmark S&P BSE Sensex was ruling 1.4 per cent higher, BSE data showed.
Jubilant FoodWorks, Indian Hotels Company and Page Industries from the consumer discretionary space; Ashok Leyland, TVS Motor Company and Bharat Forge from automobiles; AU Small Finance Bank, Muthoot Finance, Shriram Transport Finance Company and Federal Bank from financials; and Adani Transmission, Adani Power and Adani Green Energy from Adani Group were up between 3 per cent and 6 per cent on the BSE.
According to analysts, most of these stocks are surging on anticipation of improved demand that may play out post easing of travel restrictions and pick-up in vaccination drive carried out by the government. The declining daily Covid-19 caseload in the country has also boosted market sentiments.
"As domestic Covid cases fell below the 3 lakh mark for the second day in a row since mid-April, helped by the extended lockdowns by majority states, sentiments have turned buoyant. Hopes have accelerated that soon restrictions/curbs would be eased once cases decline further," said Hemang Jani, Head Equity Strategy, Broking & Distribution at Motilal Oswal Financial Services.
He added: Even the news flows around vaccination front is boosting confidence as more Pharma companies are tying up for vaccine manufacturing. Visibility on economic recovery front improves as industrial activities largely continued even during the lockdown and now. with restrictions likely to ease, consumer demand is expected to make a come-back. Thus, investors are heading more for mid-cap stocks as growing risk appetite and cheaper valuations of these companies compared to large-cap peers have revived their popularity.
Among other individual stocks from the BSE MidCap index, Gland Pharma surged 12 per cent to Rs 3,124.75 in the intra-day trade after the company reported a healthy 34 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 260.4 crore in the March 2021 quarter (Q4FY21) on robust sales. It had posted net profit of Rs 194.8 crore in Q4FY20.
The company’s revenue from operations grew 40 per cent YoY at Rs 887.70 crore from Rs 635.2 crore in a year ago quarter. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) margin during the quarter under review declined to 40 per cent from 42 per cent in previous year quarter.
The management said the new product launches, volume growth in company’s existing portfolio, along with geographic expansion, has led to strong business growth across all markets. The new Vaccine business is expected to accelerate the company’s long-term strategy of entering into Biosimilar space, the management said.
At 02:07 pm, the S&P BSE Midcap index was the top gainer among broader indices, up 1.7 per cent at 21,196.55 levels. In comparison, the S&P BSE Smallcap index was up 1.2 per cent and the benchmark S&P BSE Sensex was ruling 1.4 per cent higher, BSE data showed.
Jubilant FoodWorks, Indian Hotels Company and Page Industries from the consumer discretionary space; Ashok Leyland, TVS Motor Company and Bharat Forge from automobiles; AU Small Finance Bank, Muthoot Finance, Shriram Transport Finance Company and Federal Bank from financials; and Adani Transmission, Adani Power and Adani Green Energy from Adani Group were up between 3 per cent and 6 per cent on the BSE.
According to analysts, most of these stocks are surging on anticipation of improved demand that may play out post easing of travel restrictions and pick-up in vaccination drive carried out by the government. The declining daily Covid-19 caseload in the country has also boosted market sentiments.
"As domestic Covid cases fell below the 3 lakh mark for the second day in a row since mid-April, helped by the extended lockdowns by majority states, sentiments have turned buoyant. Hopes have accelerated that soon restrictions/curbs would be eased once cases decline further," said Hemang Jani, Head Equity Strategy, Broking & Distribution at Motilal Oswal Financial Services.
He added: Even the news flows around vaccination front is boosting confidence as more Pharma companies are tying up for vaccine manufacturing. Visibility on economic recovery front improves as industrial activities largely continued even during the lockdown and now. with restrictions likely to ease, consumer demand is expected to make a come-back. Thus, investors are heading more for mid-cap stocks as growing risk appetite and cheaper valuations of these companies compared to large-cap peers have revived their popularity.
Among other individual stocks from the BSE MidCap index, Gland Pharma surged 12 per cent to Rs 3,124.75 in the intra-day trade after the company reported a healthy 34 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 260.4 crore in the March 2021 quarter (Q4FY21) on robust sales. It had posted net profit of Rs 194.8 crore in Q4FY20.
The company’s revenue from operations grew 40 per cent YoY at Rs 887.70 crore from Rs 635.2 crore in a year ago quarter. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) margin during the quarter under review declined to 40 per cent from 42 per cent in previous year quarter.
The management said the new product launches, volume growth in company’s existing portfolio, along with geographic expansion, has led to strong business growth across all markets. The new Vaccine business is expected to accelerate the company’s long-term strategy of entering into Biosimilar space, the management said.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| Gland Pharma | 3061.00 | 2792.85 | 9.60 |
| Container Corpn. | 605.75 | 567.30 | 6.78 |
| Ashok Leyland | 121.35 | 115.45 | 5.11 |
| Jubilant Food. | 2959.50 | 2816.50 | 5.08 |
| Adani Power | 101.85 | 97.00 | 5.00 |
| Adani Transmissi | 1260.60 | 1200.60 | 5.00 |
| Adani Green | 1199.65 | 1142.55 | 5.00 |
| Info Edg.(India) | 4450.00 | 4255.85 | 4.56 |
| AU Small Finance | 984.15 | 942.10 | 4.46 |
| Supreme Inds. | 2247.95 | 2160.65 | 4.04 |
| Page Industries | 29278.85 | 28191.40 | 3.86 |
| Cummins India | 836.20 | 805.55 | 3.80 |
| Muthoot Finance | 1264.55 | 1221.35 | 3.54 |
| Indian Hotels Co | 119.20 | 115.20 | 3.47 |
| TVS Motor Co. | 638.45 | 617.10 | 3.46 |
| Shriram Trans. | 1434.70 | 1389.00 | 3.29 |
| Oberoi Realty | 543.55 | 526.50 | 3.24 |
| I R C T C | 1820.00 | 1763.55 | 3.20 |
| Federal Bank | 84.10 | 81.65 | 3.00 |
| Bharat Electron | 152.40 | 148.10 | 2.90 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%